an autoimmune disorder such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, lupus, or psoriasis received or plan to receive a stem cell transplant that uses donor stem cells had an organ transplant had radiation to your chest a condition that affects your nervous system such as ...
2.8months(range:1dayto25.6months).PatientswithNSCLCandautoimmunedisease,amedical conditionthatrequiredimmunosuppression,orwhohadreceivedmorethan30Gyofthoracicradiation withintheprior26weekswereineligibleforTrial1.Themedianageofpatientswas64years(range:28 to93),47%wereage65yearsorolder,53%weremale,83%wereWhite...
to immunotherapy, and outside of China, anti-PD-1 therapies such as pembrolizumab have become the standard therapy for this disease. With the approval of pembrolizumab in China, the treatment of advanced melanoma will now be aligned with international standards.” The approval of...
Patients with autoimmune disease, a medical condition that required systemic corticosteroids or other immunosuppressive medication; a history of interstitial lung disease; or active infection requiring therapy, including HIV or hepatitis B or C, were ineligible. The median duration of exposure was 5.6 ...
Thyroiditis included autoimmune thyroiditis, silent thyroiditis, thyroid disorder, acute thyroiditis, and immune-mediated thyroiditis. Thyroiditis occurred in 0.6% (16/2799) of patients receiving this drug, including grade 2 (0.3%). No patients discontinued this drug due to thyroiditis; this drug was...
myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy;Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual...
The key eligibility criteria for this study were metastatic squamous NSCLC, regardless of tumor PD-L1 expression status, and no prior systemic treatment for metastatic disease. Patients with autoimmune disease that required systemic therapy within two years of treatment; a medical condition that ...
“As we continue to evaluate the potential of KEYTRUDA in earlier stages of disease across multiple types of cancer, we hope to reduce disease recurrence and ultimately, improve overall survival outcomes,” said Dr. Marjorie G...
Celltrion said that it is continuing to expand its market presence in autoimmune disease treatments by “focusing on strengthening its portfolio across various therapeutic areas," with the goal of securing approval for 11 new products by 2025 to drive future growth. ...
Following AbbVie's autoimmune disease treatment, Humira (ingredient: adalimumab), Keytruda (ingredient: pembrolizumab), an immunotherapy drug from U.S. company MSD, also known as Merck in the U.S. and Canada, has emerged as the next crown jewel for biosi